Clinical Trial Update: Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study is evaluating neoadjuvant SGLT2 inhibitors for localized prostate cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• SGLT2 inhibitors (class)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Prostate Cancer, Cancer of Prostate | Phase 1 | Status: RECRUITING